Cryoport, Inc. (NASDAQ:CYRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.29.

Several equities research analysts recently weighed in on CYRX shares. Guggenheim started coverage on Cryoport in a report on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price for the company. Roth Mkm decreased their price objective on shares of Cryoport from $18.00 to $15.00 and set a "buy" rating for the company in a report on Friday, November 8th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Cryoport in a report on Friday, January 17th.

Cryoport Stock Up 1.8 %

Cryoport stock traded up $0.12 during mid-day trading on Friday, hitting $6.89. 256,184 shares of the company's stock were exchanged, compared to its average volume of 255,046. Cryoport has a 1-year low of $5.32 and a 1-year high of $20.10. The stock has a 50 day moving average of $7.72 and a two-hundred day moving average of $7.78. The stock has a market cap of $340.57 million, a P/E ratio of -2.04 and a beta of 1.59. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.

Insider Buying and Selling at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of Cryoport stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the sale, the director now owns 59,497 shares in the company, valued at $443,847.62. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jerrell Shelton sold 50,000 shares of the firm's stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $6.51, for a total transaction of $325,500.00. Following the transaction, the chief executive officer now directly owns 731,897 shares of the company's stock, valued at $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,869 shares of company stock valued at $396,673 in the last ninety days. Company insiders own 10.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after buying an additional 2,120 shares in the last quarter. Lazard Asset Management LLC bought a new stake in Cryoport during the fourth quarter worth about $51,000. Avanza Fonder AB acquired a new stake in shares of Cryoport during the fourth quarter worth approximately $64,000. Quarry LP acquired a new position in shares of Cryoport in the 4th quarter worth approximately $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Cryoport during the 3rd quarter valued at $82,000. Institutional investors and hedge funds own 92.90% of the company's stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.